ASCO 2022 Conference Coverage
Playback speed
10 seconds
ASCO 2022 on an Open-Label, Multicenter, Randomized Phase II Study of Atezolizumab & Bevacizumab With Y90 TARE in Unresectable HCC
238 views
June 23, 2022
Comments 0
Login to view comments.
Click here to Login
GI